Policy & Regulation
AmideBio names new chief executive officer
17 May 2018 -

AmideBio LLC, a privately held biopharmaceutical company, yesterday announced Dr Pawel Fludzinski as its new chief executive officer.

AmideBio said that with his extensive background developing drugs targeting diabetes at Eli Lilly & Co, Dr Fludzinski was selected as the ideal candidate to lead the company's development of its drug candidates targeting metabolic diseases. Dr Misha Plam, who has served as CEO since the company's inception, will continue as president and chairman of the board of directors.

Previously, Dr Fludzinski was global brand development leader within the Diabetes Business Unit at Lilly, where he led a cross-functional team through Phase two, Phase three and global registration of TRULICITY, Lilly's once-a-week agent for glycaemic control in type two diabetes. He held multiple executive leadership positions at Lilly in the United States, United Kingdom and Japan, encompassing roles in strategy, research and drug development. He was also one of the founding members of Lilly BioVentures.

Login
Username:

Password: